Targeting MYC-driven lymphoma:lessons learned and future directions
作者机构：Peptomyc S.L.Vall d’Hebron Barcelona Hospital CampusBarcelona 08035Spain Preclinical&Translational Research ProgramVall d’Hebron Institute of Oncology(VHIO)Vall d’Hebron Barcelona Hospital CampusBarcelona 08035Spain Department of Biochemistry and Molecular BiologyUniversitat Autònoma de BarcelonaBellaterra 08193Spain InstitucióCatalana de Recerca i Estudis Avançats(ICREA)Barcelona 08010Spain
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2023年第6卷第2期
页 面：205-222页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Fundación Cellex Ministerio de Economía y Competitividad, MINECO
主 题：High-grade B-cell lymphoma double expressor lymphoma MYC MYC therapies
摘 要：MYC plays a central role in tumorigenesis by orchestrating cell proliferation,growth and survival,among other transformation mechanisms.In particular,MYC has often been associated with lymphomagenesis.In fact,MYC overexpressing lymphomas such as high-grade B-cell lymphoma(HGBL)and double expressor diffuse large B-cell lymphomas(DLBCL),are considered addicted to MYC.In such a context,MYC targeting therapies are of special interest,as MYC withdrawal is expected to result in tumor regression.However,whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet.Even though no MYC inhibitor has received regulatory approval to date,substantial efforts have been made to investigate avenues to render MYC a druggable target.Here,we summarize the different classes of molecules currently under development,which mostly target MYC indirectly in aggressive B-cell lymphomas,paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.
维普期刊数据库